148
views
0
recommends
+1 Recommend
0 collections
    12
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In time: misuse and overuse of amino acid formulas in cow milk allergy

      editorial
      a
      Revista Paulista de Pediatria
      Sociedade de Pediatria de São Paulo

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Allergic proctocolitis and enterocolitis have been successfully treated with extensively hydrolyzed formulas for many years.1 In 1997, our group and de Boissieu et al.2 in Paris reported independently two series of patients with cow milk protein induced allergy that failed to respond to extensively hydrolyzed formulas, but ultimately responded therapeutically to an amino acid-based infant formula.3 These patients were subsequently challenged with an extensively hydrolyzed formula and indeed their symptoms recurred, confirming intolerance to the extensively hydrolyzed product. IgE binding epitopes have been demonstrated in both extensively hydrolyzed whey and casein and are thought to be responsible for these reactions.4 , 5 An amino acid-based formula was successfully utilized to treat eosinophilic esophagitis, confirming that this disorder is in fact an allergic process amenable to dietary therapy.6 The percentage of infants with cow milk protein allergy who do not tolerate an extensively hydrolyzed formula appears be low. Traditionally, the percentage is thought to be around 5%, but some have postulated that it may be on the rise.7 Despite the low incidence of intolerance to extensively hydrolyzed protein, the use of amino acid formulas has vastly exceeded the predicted usage in many countries, despite a significant increase in the cost of therapy. Commercial promotions and government reimbursement policies in some areas may have been partially responsible for this phenomenon. It is also quite true, however, that many clinicians are not aware of the literature supporting the use of extensively hydrolyzed and amino acid formulas. Amino acid formulas are sometimes utilized by clinicians because they believe the clinical response will be more rapid or the relapse rate will be significantly lower resulting in a greater degree of patient satisfaction. This is especially true when cost to the patient is not a significant deterrent. There have been no randomized studies conducted to determine the response rate to an amino acid formula versus an extensively hydrolyzed protein formula in allergic infants. Severe enterocolitis is often thought to be an indication for initial use of an amino acid formula, and even recommended in some guidelines for the management of allergic infants.8 However, no studies have ever demonstrated increased efficacy of an amino acid-based formula in this situation. Amino acid-based products are often utilized in allergic esophagitis based upon the original report demonstrating efficacy in these patients. One study, however, using an extensively hydrolyzed product in adults, demonstrated a positive symptomatic response and provided an economical alternative therapy.9 None have been done in children. Is there reason not to utilize amino acid formulas in every allergic baby other than cost? Recently, data suggest that some of the peptides present in extensively hydrolyzed formulas, especially those based on casein, may facilitate the induction of tolerance.10 , 11 Specific peptide fragments have now been identified that may play a role in this process, and this hypothesis has been preliminarily verified in animal studies.11 Earlier development of tolerance to cow milk protein of course is a much desired outcome in the treatment of allergic disease. It also appears that Lactobacillus GG, a well-studied probiotic organism (Lactobacillus rhamnosus ATC 51033), may significantly augment this process.12 It is possible other organisms might do this as well but further research is needed before such statements can be made with confidence. Nonetheless, the induction of tolerance is a key goal in allergy management and whatever can be done to facilitate this process is certainly important. Oral tolerance induction may also be possible through desensitization, and preliminary data look positive here.13 Another issue that should be addressed is the utilization of strategies to prevent or reduce the likelihood of the development of protein allergy in at risk populations. Extensively hydrolyzed casein-based formulas also play a role here, and while not equally efficacious, partially hydrolyzed whey-based formulas may also play a role. There are however conflicting data with partial hydrolysates.14 Interestingly, extensively hydrolyzed whey-based formulas do not appear to be effective.15 Finally, breast-feeding is an excellent and cost-effective way to reduce the risk of cow milk protein allergy in high-risk populations, and should be the first option if available. The probiotic Lactobacillus GG also appears to be helpful in the situation.16 Further studies are needed to determine the ideal age for introduction of proteins into the diet to prevent allergy, as some population-based studies have suggested that early introduction may be ideal.17 Food allergies, and particularly cow milk protein allergy, along with other allergies and autoimmune disorders, are becoming more common and more significant health care issues.18 The interventions discussed here and other modalities to effectively treat and prevent food allergies will become increasingly important as time progresses.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          The prevalence and natural course of food protein-induced enterocolitis syndrome to cow's milk: a large-scale, prospective population-based study.

          The prevalence and natural history for food protein-induced enterocolitis syndrome (FPIES) have not been determined. We sought to determine the prevalence, clinical manifestations, and rate of recovery for FPIES in a large-scale, population-based prospective study. In a prospective study the feeding history of 13,019 infants was obtained. Infants with probable adverse reactions to cow's milk protein (CMP) were clinically examined, skin prick tested, and challenged orally. Diagnostic criteria for CMP-induced FPIES included age less than 9 months, delayed recurrent vomiting (usually with nausea), and lethargy after exposure to CMP in the absence of other IgE-mediated symptoms, such as rash, urticaria, and respiratory symptoms. In addition, a positive challenge response to milk resulted in the above-mentioned gastrointestinal symptoms, removal of milk from the diet resulted in the resolution of those symptoms, or both. Ninety-eight percent of the cohort participated in the study. The cumulative incidence for FPIES was 0.34% (44/13,019 patients). The most common symptoms were recurrent vomiting (100%), lethargy (77%) diarrhea (25%), pallor (14%), and bloody diarrhea (4.5%). All patients had FPIES within the first 6 months of life. By the age of 3 years, 90% of the patients had recovered. We did not detect any concomitant reaction to soy. Eight patients with FPIES had IgE-mediated cow's milk allergy (IgE-CMA). The prevalence of FPIES is significant, and its clinical presentation is distinct from that of IgE-CMA. Most patients with FPIES recover, although a proportion might convert to IgE-CMA. The likelihood for a cross-reactivity to soy in this population was less than previously estimated. Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Primary prevention of food allergy in children and adults: systematic review.

            Food allergies can have serious physical, social, and financial consequences. This systematic review examined ways to prevent the development of food allergy in children and adults.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study.

              The long-term effect of nutritional intervention with hydrolysate infant formulas on allergic manifestations in high-risk children is uncertain. We sought to investigate the effect of hydrolysate infant formulas on allergic phenotypes in children with family history of allergies at school age. We analyzed data from participants of the prospective German Infant Nutritional Intervention study after 10 years of follow-up. At birth, children were randomly assigned to receive, for the first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyzed whey formula (pHF-W), extensively hydrolyzed whey formula (eHF-W), extensively hydrolyzed casein formula (eHF-C), or standard cow's milk formula. Outcomes were parent-reported, physician-diagnosed allergic diseases. Log-binomial regression models were used for statistical analysis. The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was 0.87 (95% CI, 0.77-0.99) for pHF-W, 0.94 (95% CI, 0.83-1.07) for eHF-W, and 0.83 (95% CI, 0.72-0.95) for eHF-C compared with standard cow's milk formula. The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis (n = 988) effects were stronger. The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis. The significant preventive effect on the cumulative incidence of allergic diseases, particularly AD, with pHF-W and eHF-C persisted until 10 years without rebound, whereas eHF-W showed no significant risk reduction. There is insufficient evidence of ongoing preventive activity at 7 to 10 years of age. Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Rev Paul Pediatr
                Rev Paul Pediatr
                rpp
                Revista Paulista de Pediatria
                Sociedade de Pediatria de São Paulo
                0103-0582
                1984-0462
                Oct-Dec 2015
                Oct-Dec 2015
                : 33
                : 4
                : 379-380
                Affiliations
                [a ]Boston Children's Hospital, Boston, USA
                [a ]Boston Children’s Hospital, Boston, EUA
                Author notes

                Conflicts of interest

                The author declares no conflicts of interest.

                Conflitos de interesse

                O autor declara não haver conflitos de interesse.

                Article
                10.1016/j.rpped.2015.08.003
                4685555
                26372079
                75d416fa-8b11-4b14-a6fc-a3b1a4f56b47
                © 2015 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 August 2015
                Categories
                Editorials

                Comments

                Comment on this article